Latest News & Updates

Breaking News

  • 1 hour ago

  • Vaibhavi M.

Tonix Plans Adaptive Phase 2 Trial for Seasonal Lyme Disease Prevention Therapy, Advances Program Following FDA Type C Meeting
Breaking News
Medicus Pharma Appoints Dr. Faisal Mehmud as CEO of UK Subsidiary Antev, Strengthens Leadership to Advance Global Development of Teverelix®

Vaibhavi M.

Other trending news you may like to read

Tonix Plans Adaptive Phase 2 Trial for Seasonal Lyme Disease Prevention Therapy, Advances Program Following FDA Type C Meeting

Tonix advances TNX-4800 following FDA feedback, supporting a Phase 2 study of its monoclonal antibody to prevent seasonal Lyme disease.

Vaibhavi M.

Pharma Now

Medicus Pharma Appoints Dr. Faisal Mehmud as CEO of UK Subsidiary Antev, Strengthens Leadership to Advance Global Development of Teverelix®

Medicus Pharma appoints Dr. Faisal Mehmud as CEO of Antev to lead global development of Teverelix across multiple therapeutic indications.

Vaibhavi M.

Pharma Now

Acurx Receives Positive FDA Feedback on Ibezapolstat Phase 3 Development Program, FDA Signals Potential Single-Trial NDA Pathway

Acurx receives positive FDA feedback on ibezapolstat's Phase 3 plan, supporting a potential single-trial NDA pathway for CDI treatment.

Vaibhavi M.

Pharma Now

Decoy Therapeutics Expands Global Patent Portfolio for Antiviral Technology, Strengthens Intellectual Property Around D-MAV and IMP³ACT Platform

Decoy Therapeutics expands its patent portfolio with seven patent families covering its antiviral D-MAV technology and IMP³ACT design platform.

Vaibhavi M.

Pharma Now